Scope
The AAD paediatric atopic dermatitis highlights distinguish prevention from treatment and distinguish strong from conditional recommendations. They cover skin care, topical drugs, phototherapy and systemic treatments in children and adolescents. This is a focused summary of the public recommendations: the list of supported drugs does not establish an appropriate prescription for every paediatric age, and the underlying dosing, eligibility and monitoring recommendations are not available in this extract.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Prevention is a separate decision
- Moisturizing skin care has a conditional recommendation for reducing the occurrence of atopic dermatitis. [1]
- Early food introduction, human milk consumption, and probiotic or vitamin D supplementation have conditional recommendations against their use specifically for atopic dermatitis prevention. [1]
Treatments with strong recommendations
- For treatment of paediatric atopic dermatitis, the strong recommendations support moisturizers, topical calcineurin inhibitors and topical corticosteroids. [1]
- The strong treatment recommendations also include crisaborole ointment, roflumilast cream, ruxolitinib cream and tapinarof cream. [1]
- Dupilumab, tralokinumab, lebrikizumab, upadacitinib, abrocitinib and baricitinib are included among the strongly recommended treatment options. [1]
Conditional options and recommendations against use
- Bathing, bleach baths, wet dressings, phototherapy, methotrexate, mycophenolate mofetil, azathioprine and cyclosporine have conditional recommendations in favour. [1]
- The recommendations are conditionally against topical antimicrobials and PUVA phototherapy, and strongly against systemic corticosteroids. [1]
Limitations and use
- The public highlights give no drug-specific paediatric age limits, doses, contraindications or monitoring schedules. They cannot establish licensing or availability in India.
- The conditional prevention statements address use as atopic dermatitis prevention interventions. They must not be treated as general advice to avoid breastfeeding or complementary feeding.
- Detailed comorbidity recommendations, evidence rationales and the full underlying guidelines were not acquired.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Atopic dermatitis in paediatric patients — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- AAD
- First published
- 7 April 2026
- Resource type
- Clinical practice guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.